Gilead Sciences, Inc. and Galapagos∞  NV announced the closing of the global researc≠₽¥☆h and development co←™llaboration agreement signed on July 14,  ∏↕₩2019.This agreement has received clearance from↑↕ the U.S. Federal Tr↔÷™×ade Commission under the H•↑‌&art-Scott-Rodino Antitr→&ust Improvements Act of 1976 and merger cont₹↓rol approval from the Austrian Federa✘ €₩l Competition Authority.Under ε¥×•the terms of the agreement, the closing•< & of this transaction triggerβ•✔♣s an upfront license fee payment of $3.95 bil↔☆♥↔lion by Gilead to Galapagos. In addit♠♦©ion, Gilead has made an equit≠§y investment in Galapagos of approximatel ©y $1.1 billion (or approximately €960 million®£) by subscribing for new sh←πares at a price of €140.59 per share, includ÷♠±σing issuance premium. As a result, Gilead now o→β₽wns 13,589,686 ordinεσary shares of Galapagos, rεφ&epresenting approximately 22 percent of t∑π≠'he currently outstandβ€₽λing share capital of Galapagos.ε↑÷>“We are excited to close this unique agr'™≤eement, which will generate both long-term strate &"£gic value and mutual, immediate benefits,” sai≈‍∏©d Daniel O'Day, Chairman and Chief Executive Off↔×¥icer of Gilead. “The collaboration reflects↑‌ Gilead's intent to grow our ↑ &innovation network throug←©€♠h diverse and creative partnerships.”∑™‍“This agreement is abo₽φ→★ut maximizing innovation based on dλσ πeveloping new mode of action medicineβ☆s. With the capital provided by Gi↕>lead, we aim to progress innovation t"¶™®o patients,” said Onno van de St↓≠∏Ωolpe, Chief Executive Officer of Ga‍πlapagos.In accordance with Belgian transp↕₽™φarency legislation1, Galapagos no♦♠tes that its total s←&®™hare capital currently amounts to €333,479,569↕‍.76; the total number of securities conferring α≈voting rights is 61,652,086, which§‌  is also the total number of v₩>oting rights (the “denominator”), and all secur↕≥ities conferring voting righγ€✔¶ts and all voting rights ↑¥are of the same category. The total num÷♣±ber of rights (warrants) to subscr✘÷©•ibe to not yet issued securities conferring votα§♣ing rights is 5,958,292, which equals t→γ↕he total number of voting rights that may re∏→¶sult from the exercise of these warrants. Galapa>©≥₽gos does not have any convertible bonds or sh≠★ares without voting rights outstanding.Aboφ★>ut Gilead SciencesGi∏¥¥£lead Sciences, Inc. ☆≤is a research-based biopharmaceutic✘↓φal company that discovers, develops and commerci€‍≥>alizes innovative medicines in areas of unmet∑ε" medical need. The company str  ives to transform and simpliα↕↓©fy care for people with life-threatening illn‍πesses around the world. Gilead has operations i™∏&☆n more than 35 countries worldwide, with headquar↓♥✔ters in Foster City, ₹♦•California. For more informati∏‌on on Gilead Science♣β ↕s, please visit the company’s website at ww♦δw.gilead.com.About Gal"÷←apagosGalapagos (Euronext &aλ∞φ©mp; NASDAQ: GLPG) discovers and develops sm​$ all molecule medicines with↕≠ novel modes of action, three of which sho↓♥π®w promising patient results and are currentl¥€§y in late-stage development in multiple di★✔ seases. The company’s pipeline comprises Phase 3 εβthrough to discovery programs in ÷γ inflammation, fibrosis, os↕₩teoarthritis and oth÷≤≤er indications. Gala&©pagos’ ambition is to become a leading g≠$×lobal biopharmaceutical co€ ↔₩mpany focused on the di§∞scovery, development and commercialization of inn ₹ovative medicines. More information at www.glpg∏✔™♦.com.Gilead Forward-Looking S↕​>✘tatementsThis press release includes f✘±orward-looking statements wi™©thin the meaning of the Pr✘♥ivate Securities Litigation Reform Ac‌εt of 1995, related to Gilead≥≈σ✘, Galapagos and the gl'→obal research and development ™¥collaboration agreem εent that are subject to risks, uncertainties¥β​γ and other factors. All statements other than §✔statements of historical fact are statements t‌Ωαhat could be deemed forward-looking εβ∞statements, including ®∑¥↔all statements regarding the intent, belief or♥✘>σ current expectfrom pharma focus aisathe 20≠₽₽∏19 Asia-pacific Pharmaceutical IP Leade←αδ r Summit will be held in Beijing €≈→on November 14-15, and will attract  ¥↓αmore than 500 industryλ£←Ω experts from domestic​σ and foreign pharmace≠₹‌§utical companies, bi♠♠otechnology companies, governm✘™✘¥ents, associations, law firms, ₩®intellectual property agents and other compa™®₹nies to attend.Official registration a "♠nd consultation channels:Contact：An≠₩₩nPhone: 021-65650305Email：Marketing@ze®€₽εnseegroup.comhttp://en’.zenseegroup.com/p/510934/